Locations:
SearchTrial outcomes must matter to patients, says Mikkael Sekeres, MD, MS
Mikkael Sekeres, MD, MS, Director of the Leukemia Program at Cleveland Clinic Cancer Center, recently penned an op-ed for ASH Clinical News on the importance of patients in the selection of trial outcomes.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
As editor-in-chief of the news source, Dr. Sekeres argues that many outcomes measured and reported in clinical trials have little to no value to patients in terms of survival or quality of life. He urges fellow clinicians to take Robert Frost’s “road less traveled” while using the Cleveland Browns abysmal 2016 record to identify flaws in oncology outcomes measures.
Read the full editorial here.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients